Mefpa-P Oral Suspension is a combination analgesic and antipyretic formulation containing Mefenamic Acid 100 mg and Paracetamol 250 mg per 5 ml. This preparation is indicated for the management of mild to moderate pain and fever associated with conditions such as dental pain, musculoskeletal discomfort, dysmenorrhea, and febrile illnesses. Mefenamic Acid, a non-steroidal anti-inflammatory drug (NSAID), exerts its effect by inhibiting cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins involved in pain and inflammation. Paracetamol, on the other hand, provides analgesic and antipyretic effects primarily through central inhibition of prostaglandin synthesis. The combination enhances pain relief while minimizing the required dose of each component, potentially reducing adverse effects. Mefpa-P Oral Suspension is suitable for pediatric and adult patients who require oral administration of analgesics and antipyretics. It should be used with caution in patients with a history of hypersensitivity to NSAIDs or paracetamol, hepatic or renal impairment, and gastrointestinal disorders. Dosage should be individualized based on the patient’s age, weight, and clinical condition, adhering to recommended guidelines to avoid toxicity. Consultation with a healthcare professional is advised prior to use.